During its annual event “BIG UP,” French Tech Saint-Etienne Lyon awarded the prestigious BIG Start-up of the Year trophy, recognizing a start-up that embodies innovation and vitality within the region.…
Exactly 120 years after the establishment of “Turn- und Spielverein der Farbenfabriken vorm. Friedr. Bayer & Co.”, the first Bayer sports club in Germany, Bill Anderson, CEO of Bayer AG,…
AstraZeneca’s Imfinzi (durvalumab) and Lynparza (olaparib) have been recommended for approval in the European Union (EU) for patients with primary advanced or recurrent endometrial cancer. The combination of Imfinzi plus…
AstraZeneca’s Marketing Authorisation Application (MAA) for sipavibart has been accepted under the accelerated assessment procedure by the European Medicines Agency (EMA) for the pre-exposure prophylaxis (prevention) of COVID-19 in immunocompromised…
AbbVie announced today that Robert A. Michael has taken on the role of Chief Executive Officer (CEO) and joined the company’s Board of Directors, effective immediately. As previously announced, Mr.…
MSD (known as Merck & Co., Inc. in the US and Canada) and Orion Corporation announced the mutual exercise of an option to convert their co-development and co-commercialization agreement for…
MSD, known as Merck outside the United States and Canada, will host its second-quarter 2024 sales and earnings conference call for institutional investors and analysts at 9:00 a.m. ET on…
UCB, a global biopharmaceutical company, has unveiled new research findings supporting its recently launched treatments in the generalized myasthenia gravis (gMG) portfolio. These findings will be presented at the 10th…
Sure, here’s a rewritten version of the article: Today, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has…
Biogen, headquartered in Cambridge, Massachusetts, and led by CEO Christopher A. Viehbacher, announced today the launch of “LEQEMBI®” (known as “乐意保®” in China), a humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal…
Sanofi’s CD40L monoclonal antibody, frexalimab, has demonstrated promising results in reducing a key biomarker associated with nerve cell damage in patients with relapsing multiple sclerosis (MS), suggesting potential benefits in…
Today, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of their Omicron JN.1-adapted monovalent…